Physician profile
Uma Murthy
NPI 1578515706
$4,109.78
in general payments reported to CMS, 2019-2025
32 companies · $659 in 2025
The $659 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $319 · 2021: $660 · 2022: $803 · 2023: $720 · 2024: $770 · 2025: $659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,149.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.08 | 2021-2025 | |
| Lilly USA, LLC | $561.89 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $478.56 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $442.72 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $277.31 | 2021-2025 | |
| Astellas Pharma US INC | $189.56 | 2023-2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $184.67 | 2022-2024 | Austedo Xr, Austedo |
| Pfizer INC. | $179.32 | 2020-2025 | |
| Esperion Therapeutics, INC. | $148.44 | 2021-2025 | Nexletol |
| Biohaven Pharmaceutical Holding Company Ltd. | $140.88 | 2022 | |
| Allergan, INC. | $119.54 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $96.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.65 | 2019-2021 | |
| Exact Sciences Corporation | $57.10 | 2023-2024 | Cologuard Collection Kit |
| Neurocrine Biosciences, INC. | $51.37 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $48.30 | 2022-2025 | Octrode, Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $47.23 | 2019-2021 | |
| Amarin Pharma, INC. | $42.26 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.06 | 2020-2024 | Xifaxan |
| Nevro Corp. | $35.59 | 2021 | |
| Horizon Therapeutics Plc | $30.14 | 2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $29.83 | 2024 | |
| Ironwood Pharmaceuticals, INC | $25.75 | 2021 | |
| Sumitomo Pharma America, INC. | $23.44 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $20.33 | 2022 | |
| Gilead Sciences, INC. | $19.26 | 2023 | |
| Amneal Pharmaceuticals LLC | $18.44 | 2023 | Unithroid |
| Glaxosmithkline, LLC. | $17.61 | 2024 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $16.72 | 2023 | Camzyos |
| Takeda Pharmaceuticals U.S.A., INC. | $14.60 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uma Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.